Liraglutide suppresses obesity and hyperglycemia associated with increases in hepatic fibroblast growth factor 21 production in KKAy Mice

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Nonogaki, Katsunori ^a   Hazama, Miki ^a   Satoh, Noriko ^a  

^a TOHOKU UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALOGLIPTIN; FIBROBLAST GROWTH FACTOR 21; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INSULIN; LIRAGLUTIDE; LIVER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXPERIMENTAL OBESITY; FOOD INTAKE; GLUCAGON BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HYPERGLYCEMIA; HYPOPHAGIA; INSULIN BLOOD LEVEL; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; SOCIAL ISOLATION; SYSTEMIC THERAPY; WEIGHT GAIN; WHITE ADIPOSE TISSUE; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; BODY WEIGHT; DRUG EFFECTS; EATING; GENETICS; HUMAN; METABOLISM; OBESITY; PATHOLOGY;

ADIPOSE TISSUE, WHITE; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; EATING; FIBROBLAST GROWTH FACTORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; MICE; OBESITY;

EID: 84900030527     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/751930     Document Type: Article

References (23)

1. Nonogaki K., Nozue K., Oka Y., Social isolation affects the development of obesity and type 2 diabetes in mice. Endocrinology 2007 148 10 4658 4666 2-s2.0-34748823479 10.1210/en.2007-0296
2. Holst J. J., The physiology of glucagon-like peptide 1. Physiological Reviews 2007 87 4 1409 1439 2-s2.0-35748957503 10.1152/physrev.00034.2006
3. Drucker D. J., Dritselis A., Kirkpatrick P., Liraglutide. Nature Reviews Drug Discovery 2010 9 4 267 268 2-s2.0-77950501202 10.1038/nrd3148
4. Lovshin J. A., Drucker D. J., Incretin-based therapies for type 2 diabetes mellitus. Nature Reviews Endocrinology 2009 5 5 262 269 2-s2.0-67651173077 10.1038/nrendo.2009.48
5. Feng J., Zhang Z., Wallace M. B., Stafford J. A., Kaldor S. W., Kassel D. B., Navre M., Shi L., Skene R. J., Asakawa T., Takeuchi K., Xu R., Webb D. R., Gwaltney S. L. II, Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. Journal of Medicinal Chemistry 2007 50 10 2297 2300 2-s2.0-34248999413 10.1021/jm070104l
6. Lee B., Shi L., Kassel D. B., Asakawa T., Takeuchi K., Christopher R. J., Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. European Journal of Pharmacology 2008 589 1-3 306 314 2-s2.0-46549083771 10.1016/j.ejphar.2008.04.047
7. Moritoh Y., Takeuchi K., Asakawa T., Kataoka O., Odaka H., The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. European Journal of Pharmacology 2009 602 2-3 448 454 2-s2.0-58149144587 10.1016/j.ejphar.2008.11.017
8. Moritoh Y., Takeuchi K., Asakawa T., Kataoka O., Odaka H., Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β -cell function in db/db mice. British Journal of Pharmacology 2009 157 3 415 426 2-s2.0-70349918275 10.1111/j.1476-5381.2009.00145.x
9. Nonogaki K., Suzuki M., Sanuki M., Wakameda M., Tamari T., The contribution of serotonin 5-HT2C and melanocortin-4 receptors to the satiety signaling of glucagon-like peptide 1 and liragultide, a glucagon-like peptide 1 receptor agonist, in mice. Biochemical and Biophysical Research Communications 2011 411 2 445 448 2-s2.0-79960839795 10.1016/j.bbrc.2011.06.175
10. Nagamatsu S., Ohara-Imaizumi M., Nakamichi Y., Aoyagi K., Nishiwaki C., DPP-4 inhibitor des-F-sitagliptin treatment increased insulin exocytosis from db/db mice β cells. Biochemical and Biophysical Research Communications 2011 412 4 556 560 2-s2.0-80052614033 10.1016/j.bbrc.2011.07.119
11. Nonogaki K., Suzuki M., Liraglutide suppresses the plasma levels of active and des-acyl ghrelin independently of active glucagon-like peptide-1 levels in mice. ISRN Endocrinology 2013 2013 5 184753 10.1155/2013/184753
12. Kharitonenkov A., Shiyanova T. L., Koester A., Ford A. M., Micanovic R., Galbreath E. J., Sandusky G. E., Hammond L. J., Moyers J. S., Owens R. A., Gromada J., Brozinick J. T., Hawkins E. D., Wroblewski V. J., Li D.-S., Mehrbod F., Jaskunas S. R., Shanafelt A. B., FGF-21 as a novel metabolic regulator. The Journal of Clinical Investigation 2005 115 6 1627 1635 2-s2.0-20444435873 10.1172/JCI23606
13. Berglund E. D., Li C. Y., Bina H. A., Lynes S. E., Michael M. D., Shanafelt A. B., Kharitonenkov A., Wasserman D. H., Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology 2009 150 9 4084 4093 2-s2.0-69249093921 10.1210/en.2009-0221
14. Coskun T., Bina H. A., Schneider M. A., Dunbar J. D., Hu C. C., Chen Y., Moller D. E., Kharitonenkov A., Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 2008 149 12 6018 6027 2-s2.0-57349098220 10.1210/en.2008-0816
15. Xu J., Lloyd D. J., Hale C., Stanislaus S., Chen M., Sivits G., Vonderfecht S., Hecht R., Li Y.-S., Lindberg R. A., Chen J.-L., Jung D. Y., Zhang Z., Ko H.-J., Kim J. K., Véniant M. M., Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009 58 1 250 259 2-s2.0-61649127208 10.2337/db08-0392
16. Yang M., Zhang L., Wang C., Liraglutide increases FGF-21 activity and insulin sensitivity in high fat diet and adiponectin knockdown induced insulin resistance. PLoS ONE 2012 7 11 e48392 10.1371/journal.pone.0048392
17. Inagaki T., Lin V. Y., Goetz R., Mohammadi M., Mangelsdorf D. J., Kliewer S. A., Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metabolism 2008 8 1 77 83 2-s2.0-45649085226 10.1016/j.cmet.2008.05. 006
18. Badman M. K., Koester A., Flier J. S., Kharitonenkov A., Maratos-Flier E., Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009 150 11 4931 4940 2-s2.0-70350322694 10.1210/en.2009-0532
19. Muise E. S., Azzolina B., Kuo D. W., El-Sherbeini M., Tan Y., Yuan X., Mu J., Thompson J. R., Berger J. P., Wong K. K., Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor γ and altered metabolic states. Molecular Pharmacology 2008 74 2 403 412 2-s2.0-47949111205 10.1124/mol.108.044826
20. Dutchak P. A., Katafuchi T., Bookout A. L., Choi J. H., Yu R. T., Mangelsdorf D. J., Kliewer S. A., Fibroblast growth factor-21 regulates PPAR γ activity and the antidiabetic actions of thiazolidinediones. Cell 2012 148 3 556 567 2-s2.0-84856713404 10.1016/j.cell.2011.11.062
21. Habegger K. M., Stemmer K., Cheng C., Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 2013 62 5 1453 1463 10.2337/db12-1116
22. Arafat A. M., Kaczmarek P., Skrzypski M., Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia 2013 56 3 588 597 10.1007/s00125-012-2803-y
23. Campbell J. E., Drucker D. J., Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism 2013 17 6 819 837